MedTrace Logo

Interleukin-2 in Metastatic Melanoma

NCT01702896 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2018-04-05

Study results available
· View outcomes & findings →

Summary

To determine whether Interleukin-2 at the dose and schedule will help to increase tumor shrinkage

Conditions

  • Melanoma Metastatic

Interventions

DRUG

Interleukin-2

Interleukin-2

Sponsors & Collaborators

  • Western Regional Medical Center

    lead OTHER

Principal Investigators

  • Jordan Waypa, FNP · Research Director

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2014-12-31
Completion
2014-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01702896 on ClinicalTrials.gov